University of California San Francisco
Give to UCSF
UCSF is launching the Bakar ImmunoX Initiative, an innovative research program that will promote collaborative, cutting-edge research and data sharing to catalyze discoveries about the central role of the immune system in human health and harness its power to treat a wide range of diseases.
One in seven older veterans with hypertension is discharged with increased blood pressure medications, despite half of those having well-controlled blood pressure prior to their hospital stay.
These results confirm that the HPV virus causes head and neck cancer by inactivating the same proteins that are mutated in smoking-induced cancer.
He was the heart of UCSF Radiology for the 26 years of his chairmanship, from 1963 to 1989, and led the extraordinary evolution of imaging that began with the early days of CT, MRI, US, PET-CT, interventional radiology, molecular imaging and other modalities.
Marin General Hospital (MGH) and UCSF Health have formed a strategic alliance to expand clinical collaborations in Marin County.
The new UCSF student housing complex at 590 & 600 Minnesota Street has been officially named: UCSF Housing at the Tidelands.
A new study has identified at-risk populations for whom depression screening combined with hazardous alcohol use screening could detect depressive symptoms that might otherwise go untreated.
UCSF researchers have discovered how a mutation in a gene regulator called the TERT promoter confers “immortality” on tumor cells, enabling the unchecked cell division that powers their aggressive growth.
A new spinal cord injury protocol, based on research by UCSF scientists, is a mixture of revised evaluations and new treatments to personalize care. It has spurred quicker recoveries for patients.
UCSF researchers have uncovered 12 new anti-CRISPR genes, some of which can inhibit different CRISPR types and could be critical to future gene-editing therapies.
UCSF researchers have shown that it’s possible to study cellular identity by pulverizing brain tissue samples, extracting their RNA in bulk and looking for signature patterns of gene activity.
The availability of biosimilars commonly used to treat moderate to severe RA may not by itself reduce out-of-pocket costs for Medicare beneficiaries due to a lack of manufacturer discounts.
